caa a22 4500 465738842 CHVBK 20180323111802.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF02245789 doi (NATIONALLICENCE)springer-10.1007/BF02245789 Effects of carbamazepine on 5-hydroxytryptamine function in rodents [Elektronische Daten] [M. Elphick, S. Anderson, K. Hallis, D. Grahame-Smith] The effects of carbamazepine (CBZ) on brain 5-hydroxytryptamine (5-HT) function were investigated in rodents pretreated with CBZ acutely or for 14 days. In behavioural experiments, mice pretreated with 14 days CBZ showed increased 5-HT2-mediated head twitch behaviour after injection of carbidopa (25 mg/kg) followed by 5-hydroxytryptophan (5-HTP, 100 mg/kg). However, no change in head twitches after 5-methoxy,N,N,-dimethyltryptamine (5MeODMT 5.0 mg/kg), a direct agonist, was observed. Chronic CBZ administration to rats did not alter either the behavioural syndrome induced by 8-hydroxy-2-dipropy-laminotetralin (8-OH-DPAT, 1.0 mg/kg), an index of post-synaptic 5-HT1A responses, or hypothermia after 8-OH-DPAT (0.5 mg/kg) which is thought to reflect presynaptic 5-HT1A activity. Both hyperactivity and the behavioural syndrome seen after tranylcypromine (20 mg/kg) followed byl-tryptophan (100 mg/kg) were decreased by prior treatment with CBZ (14 days). Accumulation of 5-HTP after administration of the amino acid decarboxylase inhibitor NSD1015 (100 mg/kg) was decreased after acute CBZ (50 mg/kg) in hippocampus. However, after 14 days oral treatment no change in this measure of 5-HT synthesis was seen, in either hippocampus or frontal cortex. CBZ (50 µM) added to superfused brain slices did not affect potassium-stimulated [3H]-5-HT release. However, hippocampal slices from rats pretreated with CBZ (14 days) showed increased potassium-stimulated [3H]-5-HT release. CBZ (14 days) did not alter 5-HT2 binding in rat frontal cortex. These results indicate a depressant effect of acute CBZ upon presynaptic 5-HT activity and an increase in presynaptic 5-HT function when CBZ is given for 14 days. Post-synaptic 5-HT function was, however, not altered by CBZ. Springer-Verlag, 1990 Carbamazepine nationallicence 5-HT nationallicence Behaviour nationallicence Synthesis nationallicence Release nationallicence Binding nationallicence Elphick M. MRC Unit and University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK aut Anderson S. MRC Unit and University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK aut Hallis K. MRC Unit and University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK aut Grahame-Smith D. MRC Unit and University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK aut Psychopharmacology Springer-Verlag 100/1(1990-03-01), 49-53 0033-3158 100:1<49 1990 100 213 https://doi.org/10.1007/BF02245789 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245789 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Elphick M. MRC Unit and University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK aut NATIONALLICENCE 700 1- Anderson S. MRC Unit and University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK aut NATIONALLICENCE 700 1- Hallis K. MRC Unit and University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK aut NATIONALLICENCE 700 1- Grahame-Smith D. MRC Unit and University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 100/1(1990-03-01), 49-53 0033-3158 100:1<49 1990 100 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer